This inventor holds 4 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Hadasit Medical Research Services and Development Ltd.. Active years: 2016-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2016-2022
Title: Shoshana Frankenburg: Innovator in Cancer Therapy and Immunotherapy
Introduction:
Shoshana Frankenburg, a talented inventor and researcher hailing from Jerusalem, Israel, has made significant contributions to the field of immunotherapy and cancer treatment. With a remarkable background in biotechnology, Shoshana has secured four patents, including his latest groundbreaking inventions aimed at improving T cell modulation and cancer therapeutics. This article explores his latest patents, career highlights, and collaborations, shedding light on his valuable contributions to the medical field.
Latest Patents:
Shoshana's latest patents revolve around the development of novel methods for cancer therapy using isolated NTB-A ectodomain polypeptides. These inventions provide innovative approaches for improved T cell modulation, both ex vivo and in vivo, leading to enhanced treatment options for cancer patients. Additionally, the patents highlight the use of soluble NTB-A polypeptides or agonists to prevent and treat cytopenia, a condition characterized by a low number of blood cells. These advancements pave the way for the ex vivo preparation of improved cell compositions for cancer therapy.
Career Highlights:
Shoshana Frankenburg is a dedicated researcher and a pivotal member of the esteemed Hadasit Medical Research Services and Development Company. With his expertise in immunotherapy, Shoshana has gained recognition for his significant contributions to the medical field. His patents not only demonstrate his ingenuity but also his relentless pursuit of innovative solutions for cancer treatment. Through his research work, he has emerged as a visionary in developing improved methods for T cell modulation, making notable strides in the fight against cancer.
Collaborations:
Shoshana Frankenburg has had the privilege of collaborating with esteemed colleagues, such as Michal Lotem and Arthur Machlenkin, who share his passion for medical research. These collaborations have fostered an environment of innovation, allowing Shoshana to leverage diverse expertise and insights to develop groundbreaking cancer therapies. The combined efforts of this talented team have contributed significantly to the advancement of immunotherapy and its potential to revolutionize cancer treatment.
Conclusion:
Shoshana Frankenburg's contributions to the field of immunotherapy and cancer treatment are commendable. His latest patents focusing on NTB-A ectodomain polypeptides underscore his ability to translate scientific knowledge into practical solutions for cancer therapy. As a valuable asset to the Hadasit Medical Research Services and Development Company, Shoshana's dedication and innovative mindset continue to pave the way for improved treatment options for cancer patients worldwide. His collaborations with fellow researchers further propel the advancements in immunotherapy, bringing hope to those affected by cancer.
Disclaimer: The information provided in this article is based on available data and may be subject to change or further updates. For the most accurate and up-to-date information, kindly refer to the official sources and documentation related to Shoshana Frankenburg's work and patents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile